Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

Lineage Cell Therapeutics, Inc. ( LCTX ) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease July 13, 2026 4:30 PM EDT Company Participants Ioana Hone - Director of Investor Relations Brian Culley - CEO, President & Director Priyantha Herath - Senior VP & Head of Clinical Operations Conference Call Participants Mayank Mamtani - B. Riley Securities, Inc., Research Division Yang Chen - Raymond James & Associates, Inc., Research Division Presentation Operator Welcome to the Lineage Cell Therapeutics Conference Call. Operator Instructions. An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage and recordings, reproductions or transmission of this call without the express written consent of Lineage are strictly prohibited. Operator Instructions. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead. Ioana Hone Director of Investor Relations Thank you, Angela. Good afternoon, and thank you for joining us. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements. For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statements section in today's press release and in the company's...